Jun 1
Eli Lilly and Company Retevmo shows major reduction in cancer recurrence risk trial
Eli Lilly's Retevmo cut cancer recurrence or death risk by 83% in the Phase 3 LIBRETTO-432 trial of 151 NSCLC patients. 24-month EFS hit 92%
seen from United States
seen from United States
seen from Denmark
seen from Denmark
seen from Czechia
seen from Poland
seen from Malaysia
seen from Bangladesh
seen from United States
seen from Germany
seen from Germany
seen from India
seen from Türkiye
seen from United Kingdom
seen from United Kingdom
seen from Kazakhstan
seen from United States
seen from United States
seen from Slovakia
seen from United States
Eli Lilly and Company Retevmo shows major reduction in cancer recurrence risk trial
Eli Lilly's Retevmo cut cancer recurrence or death risk by 83% in the Phase 3 LIBRETTO-432 trial of 151 NSCLC patients. 24-month EFS hit 92%